Domov › Nemalicelični pljučni rak › North Carolina

Klinične študije za Nemalicelični pljučni rak v North Carolina

79 študij za Nemalicelični pljučni rak išče udeležence na lokacijah v North Carolina.

Mesta v North Carolina

Uradno besedilo študije (angleško)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Cone Health MedCenter Asheboro, Asheboro
Cone Health Cancer Center at Alamance Regional, Burlington
Wake Forest University at Clemmons, Clemmons
in še 7

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT04267848

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Novant Health Weisiger Cancer Insititute ( Site 0266), Charlotte
Novant Health Forsyth Medical Center ( Site 0166), Winston-Salem

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06623422

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT07293247

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Duke University, Durham

Vključevanje udeležencevFaza 1/2

Starost 12 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT04585750

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

Carolina Cancer Research Center, Wilson

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06270706

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #12, Durham

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT05176483

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

Charles George VA Medical Center ( Site 3233), Asheville
UNC Lineberger Comprehensive Cancer Center ( Site 3250), Chapel Hill
WakeMed Raleigh Campus ( Site 3214), Raleigh

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT07513376

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT07388524

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

WakeMed Raleigh Campus ( Site 0144), Raleigh

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT07554339

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Duke Cancer Center Cary, Cary
Durham VA Medical Center, Durham
Duke University Medical Center, Durham
in še 2

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 1. okt. 2026 · NCT06498635

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Novant Health Pharmacy Oncology Specialists, Winston-Salem

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07361497

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Novant Health Pharmacy Oncology Specialists, Winston-Salem

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07361510

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Carolinas Medical Center, Charlotte
Duke Cancer Center, Durham

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT06765109

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

UNC Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT06881784

A Study of PHN-012 in Patients With Advanced Solid Tumors

PHN-012-001 Site, Durham

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 29. sep. 2026 · NCT07127874

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

FirstHealth Cancer Center, Pinehurst
FirstHealth Moore Regional Hospital, Pinehurst
Carolina Cancer Research Center, Wilson

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07222566

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Messino Cancer Centers Asheville, Asheville
Duke University Medical Center, Durham
FirstHealth Cancer Center, Pinehurst

Vključevanje udeležencevFaza 3

Starost 18–100 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT05920356

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Levine Cancer Institute, Charlotte
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT04253964

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Brody School of Medicine at East Carolina University, Greenville
ECU Health Medical Center, Greenville
Carolina Cancer Research Center, Wilson

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06758401

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Atrium Health, Charlotte
Regional Medical Oncology Center, Wilson
Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06667076

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

University of North Carolina at Chapel Hill, Chapel Hill
FirstHealth of the Carolinas, Pinehurst

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06667908

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

WakeMed Raleigh Campus, Raleigh

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06890598

Pan-tumor MRD Study

Carolina Oncology Specialists, Charlotte
Southeastern Medical Oncology Center (SMOC), Goldsboro
Regional Medical Oncology Center, Wilson

Vključevanje udeležencevOpazovalna študija

Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06605404

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT03191149

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

East Carolina University, Greenville

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT06561386

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Research Site, Greenville
Research Site, Salisbury

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT06357533

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Fletcher Hospital, Inc. dba AdventHealth Hendersonville, Hendersonville

Vključevanje udeležencevFaza 2/3

Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT06712316

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

FirstHealth of the Carolinas- Speciality Center /ID# 272924, Pinehurst

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT06568939

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

Atrium Health Levine Cancer, Charlotte
Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT05696782

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Duke Cancer Center Durham, Durham

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07488676

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Local Institution - 0624, Asheville

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT06875310

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

FirstHealth of the Carolinas, Inc., Pinehurst

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT06745882

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site, Wilson

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 18. sep. 2026 · NCT06692738

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical Study Site, Chapel Hill
Clinical Study Site, Durham
Clinical Study Site, Pinehurst

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 18. sep. 2026 · NCT06767514

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Carolina Biooncology Institute, Huntersville

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 18. sep. 2026 · NCT05267626

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Levine Cancer Institute, Charlotte
Durham VA Health Care System, Durham

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT07195695

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Duke University School of Medicine, Durham

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 16. sep. 2026 · NCT05786924

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Duke University Medical Center, Durham

Vključevanje udeležencevFaza 2/3

Starost 18 in več · Vsi spoli · Posodobljeno 16. sep. 2026 · NCT04613596

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

FirstHealth Cancer Center, Pinehurst
Carolina Cancer Research Center, Wilson

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 15. sep. 2026 · NCT06899126

Effects of Infusion Timing on Treatment Response in Solid Tumors

University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 15. sep. 2026 · NCT07630168

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.